Thomas Catinazzo compensation by year
Relay Therapeutics Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $381,100 | $420,000 | $465,000 | $481,276 | $486,100 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $543,548 | $800,323 | $1,855,945 | $3,713,903 | $0 |
| Option awards | $734,038 | $1,057,117 | $2,699,210 | $0 | $874,500 |
| Non-equity incentive | $166,731 | $168,000 | $186,000 | $192,510 | $194,440 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $10,862 | $11,825 | $12,994 | $13,305 | $13,573 |
| Total | $1,836,279 | $2,457,265 | $5,219,149 | $4,400,994 | $1,568,613 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Relay Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001193125-26-186929, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Relay Therapeutics, Inc. filed document, accession 0001193125-26-186929. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 48,815 | $412,975 | — |
| RSU | 25,000 | $211,500 | — |
| PSU | 17,394 | $147,153 | — |
| RSU | 16,344 | $138,270 | — |
| RSU | 2,455 | $20,769 | — |
| Option | 223,438 | — | $4.45 |
| Option | 4,909 | — | $20.38 |
| Option | 32,688 | — | $20.45 |
| Option | 97,630 | — | $20.45 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Relay Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
19 Form 4 lines since the FY2025 proxy (filed April 28, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-28 | Sale | — | 1,469 | $18.62 | 103,665 |
| 2026-10-06 | Sale | 10b5-1 | 17,511 | $18.58 | 105,340 |
| 2026-10-06 | Sale | 10b5-1 | 206 | $19.26 | 105,134 |
| 2026-09-08 | Sale | 10b5-1 | 17,717 | $18.94 | 122,851 |
| 2026-08-14 | Sale | 10b5-1 | 17,717 | $19.74 | 140,568 |
| 2026-07-28 | Sale | — | 1,459 | $18.61 | 158,285 |
| 2026-07-06 | Sale | 10b5-1 | 17,717 | $18.69 | 159,744 |
| 2026-06-22 | Exercise or conversion derivative | 10b5-1 | 56,323 | $0.00 | 0 |
The 8 most recent of 19 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Relay Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $680,540 | $0 | $0 | $680,540 |
| Resignation for good reason, no change in control | $680,540 | $0 | $0 | $680,540 |
| Change in control and involuntary termination | $680,540 | $1,266,526 | $0 | $1,947,066 |
| Change in control and resignation for good reason | $680,540 | $1,266,526 | $0 | $1,947,066 |
Per the Potential Payments Upon Termination or Change in Control table in Relay Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Relay Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sanjiv Patel | President and Chief Executive Officer | $4,646,454 |
| Donald Bergstrom | President, Research & Development | $2,089,663 |
| Thomas Catinazzo · this page | Chief Financial Officer | $1,568,613 |
| Peter Rahmer | Chief Corporate Development Officer | $1,545,170 |
| Brian Adams | Former Chief Legal Officer | $1,177,329 |
Thomas Catinazzo's compensation dossier, Relay Therapeutics
You have read Thomas Catinazzo's totals and holdings. The dossier adds each equity grant Relay Therapeutics disclosed for Thomas Catinazzo and Relay Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Relay Therapeutics compensation record
free company briefThis page is one person within Relay Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Relay Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Relay Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Relay Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order RLAY
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.